Trastuzumab and target-therapy side effects: Is still valid to differentiate anthracycline Type I from Type II cardiomyopathies?
Gennaro Riccio(Sapienza University of Rome), Nicola Maurea(Cancer Institute (WIA)), Carlo Maurea(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Carmela Coppola, Claudia De Lorenzo(Istituto Nazionale di Fisica Nucleare, Sezione di Napoli), Immacolata Capasso(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Emanuela Esposito(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Giovanna Piscopo(University of Cagliari)
Cited by 55
Related Papers
Fish Waste: From Problem to Valuable Resource
|Marine Drugs|2021|568
The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin
|Cardiovascular Diabetology|2021|368
Microalgae with Immunomodulatory Activities
|Marine Drugs|2019|184
Trastuzumab Adjuvant Chemotherapy and Cardiotoxicity in Real-World Women With Breast Cancer
|Journal of Cardiac Failure|2011|116
Metabolic syndrome affects breast cancer risk in postmenopausal women: National Cancer Institute of Naples experience
|Cancer Biology & Therapy|2010|108